Acted as Cayman Islands counsel to Sunho Biologics, Inc. ("Sunho Biologics") in relation to its initial public offering of 34,151,800 shares and the listing on the Hong Kong Stock Exchange. Sunho Biologics is a clinical stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. The offering, which closed on 24 May 2024, raised approximately HK$461 million. The Maples team comprised of partner Derrick Kan and legal manager Charmaine Chow. The Group's Fund Services business acted as the Cayman Islands Share Registrar, and the team comprised Eastern Fong, Regional Head of the Group's fund services business in Asia and senior vice president Christy Poon. Sunho Biologics was also advised by O'Melveny & Myers as to Hong Kong law, and Jingtian & Gongcheng as to PRC law. The sole sponsor, China International Capital Corporation Hong Kong Securities Limited, was advised by Herbert Smith Freehills as to Hong Kong law, and by Jia Yuan Law Offices as to PRC law.
PRESS RELEASE
6 June 2024
Sunho Biologics Inc. – HK IPO - Closed On 24 May 2024
Maples Group
Contributor
The Maples Group is a leading service provider offering clients a comprehensive range of legal services on the laws of the British Virgin Islands, the Cayman Islands, Ireland, Jersey and Luxembourg, and is an independent provider of fiduciary, fund services, regulatory and compliance, and entity formation and management services.
Acted as Cayman Islands counsel to Sunho Biologics, Inc. ("Sunho Biologics") in relation to its initial public offering of 34,151,800 shares and the listing on the Hong Kong Stock Exchange.